A Prospective Observational Study on Outcomes of Hepatitis B, Hepatitis C Patients in Gastroenterology Department of Tertiary Care Hospital

Authors

  • Sreenu Thalla
  • R. Kamaraj
  • A. Kavitha

Keywords:

HCV, Treatment, Direct-acting antivirals (DAAs), HBV, Viral load

Abstract

Oral direct-acting antiviral (DAA) therapies have significantly improved the treatment outcomes for chronic hepatitis C virus (HCV) infection, achieving sustained virological response (SVR) rates exceeding 95%. However, co-infection with hepatitis B virus (HBV) and HCV presents greater clinical complexity than mono-infection with either virus. In this study, we evaluated the incidence of HBV reactivation during and three months post-DAA therapy, as well as the SVR rate at 12 weeks in patients with HBV/HCV co-infection. Among the study cohort, 361 patients (95.5%) achieved SVR. Factors associated with failure to achieve SVR included older age, lower platelet count, elevated blood creatinine levels, and increased liver stiffness measured by FibroScan. HBV reactivation occurred in 13 patients (4%), who had significantly higher baseline levels of ALT, serum creatinine, and HCV RNA viral load compared to those without reactivation. While DAA therapy is highly effective in achieving SVR in HBV/HCV co-infected patients, careful monitoring is essential due to the risk of HBV reactivation during and after treatment.

Downloads

Download data is not yet available.

References

Mavilia MG, Wu GY (2018). HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol 6:296–305

Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T et al (2017). Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the US Food and Drug Administration Adverse Event Reporting System. Ann Intern Med 166:792–798

Coppola N, De Pascalis S, Onorato L, Calo F, Sagnelli C, Sagnelli E (2016). Hepatitis B virus and hepatitis C virus infection in healthcare workers. World J Hepatol 8:273–281

Mucke MM, Backus LI, Mucke VT, Coppola N, Preda CM, Yeh ML et al (2018). Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 3:172–180

Hwang JP, Lok AS (2014). Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 11:209–219

Peeling RW, Boeras DI, Marinucci F, Easterbrook P (2017). The future of viral hepatitis testing: innovations in testing technologies and approaches. BMC Infect Dis 17:187–196

Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H et al (2018). Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther 47:421–431.

Wang C, Ji D, Chen J, Shao Q, Li B, Liu J et al (2017). Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 15:132–136

Soliman EMK, Morsy HAA, Othman AMM, Mady AM (2020). Predictor factors of sustained virological response in patients with chronic hepatitis C treated with current direct-acting antiviral drugs. Trop J Pharm Res 19:2015–2020.

Kawagishi N, Suda G, Onozawa M, Kimura M, Maehara O, Ohara M et al (2017). Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat 24(12):1098–1106

El Kassas M, Shimakawa Y, Ali-Eldin Z, Funk A, Wifi MN, Zaky S et al (2018). Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: a cohort study from Egypt and meta-analysis of published data. Liver Int 38:2159–2169

Doi A, Sakamori R, Tahata Y, Urabe A, Morishita N, Yamada R et al (2017). Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: analysis of a Japanese prospective cohort. Hepatol Res 47:1438–1444.

Shousha HI, Saad Y, Saleh DA, Dabes H, Alserafy M, ElShazly Y et al (2020). Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 32:1017–1022

Downloads

Published

2025-06-18

How to Cite

1.
Thalla S, Kamaraj R, Kavitha A. A Prospective Observational Study on Outcomes of Hepatitis B, Hepatitis C Patients in Gastroenterology Department of Tertiary Care Hospital. J Neonatal Surg [Internet]. 2025Jun.18 [cited 2025Oct.10];14(8):476-80. Available from: https://www.jneonatalsurg.com/index.php/jns/article/view/7470

Issue

Vol. 14 No. 8 (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.